Citizens Reiterates Market Outperform on Acrivon Therapeutics, Maintains $13 Price Target

Benzinga · 4d ago
Citizens analyst Silvan Turkcan reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Market Outperform and maintains $13 price target.